Synthetic peptide F2A4-K-NS mimics fibroblast growth factor-2 in vitro and is angiogenic in vivo

International Journal of Molecular Medicine

Volumn 17, Issue 5, 2006, Pages 833-839

  Lin, X ^a,b   Takahashi, K ^b   Campion, S L ^b   Liu, Y ^b   Gustavsen, G G ^c   Pena L A ^a,c   Zamora, P O ^b  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b Biosurface Eng Technologies Inc   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Angiogenesis; F2A4 K NS peptide; Fibroblast growth factor

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OLIGOPEPTIDE; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANIMAL; ARTICLE; C57BL MOUSE; CELL LINE; CELL MOTION; CELL PROLIFERATION; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MOUSE; PHOSPHORYLATION; PROTEIN BINDING; SURFACE PLASMON RESONANCE; SYNTHESIS;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGOPEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE;

EID: 33748558849     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.17.5.833     Document Type: Article

References (30)

1. Nugent MA and Iozzo RV: Fibroblast growth factor-2. Int J Biochem Cell Biol 32: 115-120, 2000.
2. Powers CJ, McLeskey SW and Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 7: 165-197, 2000.
3. Battegay EJ: Angiogenesis: mechanistic insights, neovascular diseases and therapeutic prospects. J Mol Med 73: 333-346, 1995.
4. Sakurai T, Satake A, Sumi S, Inoue K, Nagata N, Tabata Y and Miyakoshi J: The efficient prevascularization induced by fibroblast growth factor 2 with a collagen-coated device improves the cell survival of a bioartificial pancreas. Pancreas 28: E70-E79, 2004.
5. Schnettler R, Alt V, Dingeldein E, Pfefferle HJ, Kilian O, Meyer C, Heiss C and Wenisch S: Bone ingrowth in bFGF-coated hydroxyapatite ceramic implants. Biomaterials 24: 4603-4608, 2003.
6. Van der Bas JM, Quax PH, van den Berg AC, Visser MJ, van der Linden E and van Bockel JH: Ingrowth of aorta wall into stent grafts impregnated with basic fibroblast growth factor: a porcine in vivo study of blood vessel prosthesis healing. J Vasc Surg 39: 850-858, 2004.
7. Hatano T, Miyamoto S, Kawakami O, Yamada K, Hashimoto N and Tabata Y: Acceleration of aneurysm healing by controlled release of basic fibroblast growth factor with the use of polyethylene terephthalate fiber coils coated with gelatin hydrogel. Neurosurgery 53: 391-400, 2003.
8. Matsumoto H, Terada T, Tsuura M, Itakura T and Ogawa A: Basic fibroblast growth factor released from a platinum coil with a polyvinyl alcohol core enhances cellular proliferation and vascular wall thickness: an in vitro and in vivo study. Neurosurgery 53: 402-408, 2003.
9. Chen WJ, Jingushi S, Aoyama I, Anzai J, Hirata G, Tamura M and Iwamoto Y: Effects of FGF-2 on metaphyseal fracture repair in rabbit tibiae. J Bone Miner Metab 22: 303-309, 2004.
10. Kawaguchi H, Nakamura K, Tabata Y, Ikada Y, Aoyama I, Anzai J, Nakamura T, Hiyama Y and Tamura M: Acceleration of fracture healing in non-human primates by fibroblast growth factor-2. J Clin Endocrinol Metab 86: 875-880, 2001.
11. Nakamura T, Hara Y, Tagawa M, Tamura M, Yuge T, Fukuda H and Nigi H: Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. J Bone Miner Res 13: 942-949, 1998.
12. Radomsky ML, Thompson AY, Spiro RC and Poser JW: Potential role of fibroblast growth factor in enhancement of fracture healing. Clin Orthop 335 (Suppl): S283-S293, 1998.
13. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G and Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem 271: 15292-15297, 1996.
14. Baird A, Schubert D, Ling N and Guillemin R: Receptor- and heparin-binding domains of basic fibroblast growth factor. Proc Natl Acad Sci USA 85: 2324-2328, 1988. (Pubitemid 24315884)
15. Ray J, Baird A and Gage FH: A 10-amino acid sequence of fibroblast growth factor 2 is sufficient for its mitogenic activity on neural progenitor cells. Proc Natl Acad Sci USA 94: 7047-7052, 1997.
16. Verrecchio A, Germann MW, Schick BP, Kung B, Twardowski T and San Antonio JD: Design of peptides with high affinities for heparin and endothelial cell proteoglycans. J Biol Chem 275: 7701-7707, 2000.
17. Sheehan JP, Kobbervig CE and Kirkpatrick HM: Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa. Biochemistry 42: 11316-11325, 2003.
18. Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC and Goligorsky MS: Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 45: 598-604, 1994.
19. Tsukahara H, Ende H, Magazine HI, Bahou WF and Goligorsky MS: Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem 269: 21778-21785, 1994.
20. Lee MS, Moon EJ, Lee SW, Kim MS, Kim KW and Kim YJ: Angiogenic activity of pyruvic acid in in vivo and in vitro angiogenesis models. Cancer Res 61: 3290-3293, 2001.
21. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS and Martin GR: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblast growth factor. Lab Invest 67: 519-528, 1992.
22. Lucidarme O, Nguyen T, Kono Y, Corbeil J, Choi SH, Varner J and Mattrey RF: Angiogenesis model for ultrasound contrast research: exploratory study. Acad Radiol 11: 4-12, 2004.
23. Pellegrini L, Burke DF, von Delft F, Mulloy B and Blundell TL: Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407: 1029-1034, 2000.
24. Ibrahimi OA, Yeh BK, Eliseenkova AV, Zhang F, Olsen SK, Igarashi M, Aaronson SA, Linhardt RJ and Mohammadi M: Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization. Mol Cell Biol 25: 671-684, 2005.
25. Ibrahimi OA, Zhang F, Hrstka SC, Mohammadi M and Linhardt RJ: Kinetic model for FGF, FGFR and proteoglycan signal transduction complex assembly. Biochemistry 43: 4724-4730, 2004.
26. Allen DL, Teitelbaum DH and Kurachi K: Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro. Am J Physiol 284: C805-C815, 2003.
27. Weston CA and Weeks BS: bFGF stimulates U937 cell adhesion to fibronectin and secretion of gelatinase B. Biochem Biophys Res Commun 228: 318-323, 1996.
28. Murphy AN, Unsworth EJ and Stetler-Stevenson WG: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157: 351-358, 1993.
29. Ornitz DM: FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 22: 108-112, 2000.
30. Pellegrini L: Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 11: 629-634, 2001.